Home › Trials › NCT05725954
Clinical trial No longer in our active list Interventional

A care pathway for managing irritable bowel syndrome and GI disorders

Official title: GUT LINK: A Pilot Study to Evaluate the Comparative Effectiveness of an Evidence-based Care Pathway Across Primary and GI Specialty Care

Run by Nova Scotia Health Authority · NCT05725954 · Data updated 2026-05-14

This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.

This study is testing a new care plan to help doctors better diagnose and treat irritable bowel syndrome and other gut issues using a special support tool.

Quick facts

Study typeInterventional
SexAll
Enrollment120 (estimated)
SponsorNova Scotia Health Authority
Academic / other
Locations1 site (Halifax, Nova Scotia)
Trial IDNCT05725954 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are general practitioners in Nova Scotia who treat patients with lower GI complaints and use the 'virtual hallway' platform for referrals.

Probably not a fit

Patients who do not have access to primary care or those with severe gastrointestinal conditions requiring immediate specialist intervention may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to implement and evaluate a Clinical Care Pathway designed to assist primary healthcare providers in diagnosing and managing irritable bowel syndrome (IBS) and other gastrointestinal disorders. By utilizing evidence-based guidelines, the study seeks to improve the differentiation between IBS and more serious gastrointestinal conditions. The intervention involves the GUT LINK SmartPath platform, which supports healthcare providers in delivering care to patients with lower GI complaints. The pilot study will assess the effectiveness of this care pathway in a real-world setting.

Why it matters

Potential benefit: If successful, this approach could enhance the accuracy of IBS diagnoses and improve patient management in primary care settings.

How similar studies have gone: While the approach of implementing care pathways is established, this specific study's focus on IBS and GI disorders through a virtual platform is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Must be a general practitioner
* Have a family practice in Nova Scotia, Canada
* Utilize the platform 'virtual hallway' as part of current referral practices
* Deliver care to patients with lower GI complaints

Exclusion Criteria:

* None

Where it's running

  • QEII Health Sciences Centre
    Halifax, Nova Scotia, Canada     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

  • Liver Fat and Scarring in People Suspected of Non-Celiac Wheat Sensitivity

    This study looks to see if people with non-celiac wheat sensitivity have liver fat or fibrosis and how this relates to IBS/FD and celiac disease.

    Recruiting at 2 sites University of Palermo · Palermo, Palermo and 1 other locations · NCT07750535

  • Repeated transcranial magnetic stimulation to treat diarrhea-predominant irritable bowel syndrome

    This study will test whether repeated transcranial magnetic stimulation (rTMS) can reduce diarrhea, abdominal pain, and improve quality of life in adults with IBS-D.

    Recruiting The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07581756

  • Brenipatide (LY3537031) for IBS with constipation

    This trial will test whether brenipatide (LY3537031), given by a small under-the-skin injection, helps adults with IBS-C have less belly pain and more normal bowel movements compared with a placebo.

    Recruiting at 64 sites Phase 2 Eli Lilly and Company · Mesa, Arizona and 69 other locations · NCT07545772

  • Brenipatide (LY3537031) treatment for adults with IBS‑D

    This will test whether brenipatide (LY3537031) given under the skin helps adults with IBS‑D reduce belly pain and improve stool consistency compared with placebo.

    Recruiting at 80 sites Phase 2 Eli Lilly and Company · Mesa, Arizona and 88 other locations · NCT07545759

  • Camlipixant for IBS-D and IBS-M: a test in adults

    This study tests camlipixant versus placebo in adults with IBS with diarrhea or mixed IBS to see if it helps reduce symptoms and is safe.

    Recruiting at 114 sites Phase 2 GlaxoSmithKline · Anniston, Alabama and 113 other locations · NCT07519395

  • Defining Objective Markers of Dietary Compliance in IBS

    This study tests whether a biomarker in stool or urine can reflect how much certain carbohydrates you eat, helping manage IBS.

    Recruiting University of Michigan · Ann Arbor, Michigan · NCT07494968

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Irritable Bowel Syndrome 75Nova Scotia Health Authority 47
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.